Bordetella pertussis isolates in Finland:: Serotype and fimbrial expression

被引:29
|
作者
Heikkinen, Eriikka [1 ]
Xing, Dorothy K. [2 ]
Olander, Rose-Marie [3 ]
Hytonen, Jukka [4 ]
Viljanen, Matti K. [4 ]
Mertsola, Jussi [5 ]
He, Qiushui [1 ]
机构
[1] Natl Publ Hlth Inst, Pertussis Reference Lab, Turku 20520, Finland
[2] Natl Inst Biol Stand & Controls, Potters Bar EN6 3QG, Herts, England
[3] Natl Publ Hlth Inst, Dept Vaccine, SF-00300 Helsinki, Finland
[4] Univ Turku, Dept Med Microbiol & Immunol, FIN-20520 Turku, Finland
[5] Turku Univ Hosp, Dept Pediat, FIN-20520 Turku, Finland
基金
芬兰科学院;
关键词
D O I
10.1186/1471-2180-8-162
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: Bordetella pertussis causes whooping cough or pertussis in humans. It produces several virulence factors, of which the fimbriae are considered adhesins and elicit immune responses in the host. B. pertussis has three distinct serotypes Fim2, Fim3 or Fim2,3. Generally, B. pertussis Fim2 strains predominate in unvaccinated populations, whereas Fim3 strains are often isolated in vaccinated populations. In Finland, pertussis vaccination was introduced in 1952. The whole-cell vaccine contained two strains, 18530 (Fim3) since 1962 and strain 1772 (Fim2,3) added in 1976. After that the vaccine has remained the same until 2005 when the whole-cell vaccine was replaced by the acellular vaccine containing pertussis toxin and filamentous hemagglutinin. Our aims were to study serotypes of Finnish B. pertussis isolates from 1974 to 2006 in a population with > 90% vaccination coverage and fimbrial expression of the isolates during infection. Serotyping was done by agglutination and serotype-specific antibody responses were determined by blocking ELISA. Results: Altogether, 1,109 isolates were serotyped. Before 1976, serotype distributions of Fim2, Fim3 and Fim2,3 were 67%, 19% and 10%, respectively. From 1976 to 1998, 94% of the isolates were Fim2 serotype. Since 1999, the frequency of Fim3 strains started to increase and reached 83% during a nationwide epidemic in 2003. A significant increase in level of serum IgG antibodies against purified fimbriae was observed between paired sera of 37 patients. The patients infected by Fim3 strains had antibodies which blocked the binding of monoclonal antibodies to Fim3 but not to Fim2. Moreover, about one third of the Fim2 strain infected patients developed antibodies capable of blocking of binding of both anti-Fim2 and Fim3 monoclonal antibodies. Conclusion: Despite extensive vaccinations in Finland, B. pertussis Fim2 strains were the most common serotype. Emergence of Fim3 strains started in 1999 and coincided with nationwide epidemics. Results of serotype-specific antibody responses suggest that Fim2 strains could express Fim3 during infection, showing a difference in fimbrial expression between in vivo and in vitro.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] FIMBRIAL PHASE VARIATION IN BORDETELLA-PERTUSSIS - A NOVEL MECHANISM FOR TRANSCRIPTIONAL REGULATION
    WILLEMS, R
    PAUL, A
    VANDERHEIDE, HGJ
    TERAVEST, AR
    MOOI, FR
    [J]. EMBO JOURNAL, 1990, 9 (09): : 2803 - 2809
  • [22] EXPRESSION OF BORDETELLA-PERTUSSIS FIMBRIAL (FIM) GENES IN BORDETELLA-BRONCHISEPTICA - FIMX IS EXPRESSED AT A LOW-LEVEL AND VIR-REGULATED
    RIBOLI, B
    PEDRONI, P
    CUZZONI, A
    GRANDI, G
    DEFERRA, F
    [J]. MICROBIAL PATHOGENESIS, 1991, 10 (05) : 393 - 403
  • [23] Bordetella pertussis vaccine strains and circulating isolates in Serbia
    Dakic, Gordana
    Kallonen, Teemu
    Elomaa, Annika
    Pljesa, Tatjana
    Vignjevic-Krastavcevic, Mirjana
    He, Qiushui
    [J]. VACCINE, 2010, 28 (05) : 1188 - 1192
  • [24] Genome characteristics of Bordetella pertussis isolates from Tunisia
    Ben Fraj, Ikram
    Bouchez, Valerie
    Smaoui, Hanen
    Kechrid, Amel
    Brisse, Sylvain
    [J]. JOURNAL OF MEDICAL MICROBIOLOGY, 2019, 68 (09) : 1320 - 1323
  • [25] Antimicrobial susceptibility of Bordetella pertussis isolates in the state of Washington
    Galanakis, Emmanouil
    Englund, Janet A.
    Abe, Patrick
    Qin, Xuan
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 (05) : 609 - 611
  • [26] Bordetella pertussis isolates with a heterogeneous phenotype for erythromycin resistance
    Wilson, KE
    Cassiday, PK
    Popovic, T
    Sanden, GN
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (08) : 2942 - 2944
  • [27] Bordetella pertussis and pertactin-deficient clinical isolates: lessons for pertussis vaccines
    Hegerle, Nicolas
    Guiso, Nicole
    [J]. EXPERT REVIEW OF VACCINES, 2014, 13 (09) : 1135 - 1146
  • [28] Strain variation among Bordetella pertussis isolates in Finland, where the whole-cell pertussis vaccine has been used for 50 years
    Elomaa, A
    Advani, A
    Donnelly, D
    Antila, M
    Mertsola, J
    Hallander, H
    He, QS
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (08) : 3681 - 3687
  • [29] Development of a qualitative assay for screening of Bordetella pertussis isolates for pertussis toxin production
    Gates, Irina
    DuVall, Marina
    Ju, Hong
    Tondella, M. Lucia
    Pawloski, Lucia
    [J]. PLOS ONE, 2017, 12 (04):
  • [30] Analysis of bvgR expression in Bordetella pertussis
    Merkel, TJ
    Boucher, PE
    Stibitz, S
    Grippe, VK
    [J]. JOURNAL OF BACTERIOLOGY, 2003, 185 (23) : 6902 - 6912